A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
ChromaDex Corporation and Nestlé Health Science agreement includes global commercial license and supply agreement for ingredient sales of TRU NIAGEN® for certain products within the medical nutrition and consumer health categories. LOS ANGELES, Dec. 20, 2018...
TRU NIAGEN® receives Natural Product Number from Health Canada and is approved for sale in the country to consumers and healthcare practitioners LOS ANGELES, Dec. 17, 2018 -- ChromaDex Corp. (NASDAQ:CDXC) announced today it has officially launched TRU...
Dr. Charles Brenner to deliver scientific presentation and "Father of Biohacking" Dave Asprey to sign copies of his new book, Game Changers LOS ANGELES, Dec. 12, 2018 -- ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature TRU NIAGEN® (Booth #6095) at...
LOS ANGELES, Nov. 28, 2018 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Co-Founder & Executive Chairman, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 11th annual LD Micro Main Event at...
ChromaDex expands TRU NIAGEN® product line, offering single-serving stick packs for on-the-go consumers and athletes LOS ANGELES, Nov. 20, 2018 -- ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of TRU NIAGEN stick packs, offering a new delivery method...
- Third Quarter 2018 Net Revenues Increased by 33% to $8.1 Million - Third Quarter 2018 Highlights vs. Third Quarter 2017 Net sales up 33%, fueled by growth of TRU NIAGEN®, which increased by 97%;TRU NIAGEN sales at 84% of NIAGEN-related sales, up from 60%Gross...
LOS ANGELES, Nov. 06, 2018 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation, effective immediately. Roberts brings over 30 years of experience in scientific...
LOS ANGELES, Oct. 31, 2018 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., Nov. 7, 2018 at 4:30 p.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2018. The financial results will be...
TRU NIAGEN® (nicotinamide riboside) receives best product award and recognized as top seller in 2018 amongst Watsons Hong Kong members LOS ANGELES, Oct. 30, 2018 -- ChromaDex Corp. (NASDAQ:CDXC) announced today its TRU NIAGEN® product was recognized as "The...
Inaugural event aims to empower women on critical health issues that arise after age 45 LOS ANGELES, Oct. 25, 2018 -- ChromaDex Corp. (NASDAQ:CDXC) announced today its TRU NIAGEN® (nicotinamide riboside) nutrient will be featured at the inaugural One-Day Medical...